Abstract:Blocking HIV-1 cell entry has long been a major goal of anti-HIV drug development. Here, we report a successful design of two highly potent chimeric HIV entry inhibitors composed of one CCR5-targeting RANTES (regulated on activation normal T cell expressed and secreted) variant (5P12-RANTES or 5P14-RANTES (Gaertner, H., Cerini, F., Escola, J. M., Kuenzi, G., Melotti, A., Offord, R., Rossitto-Borlat, I., Nedellec, R., Salkowitz, J., Gorochov, G., Mosier, D., and Hartley, O. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 17706-17711)) linked to a gp41 fusion inhibitor, C37. Chimeric inhibitors 5P12-linker-C37 and 5P14-linker-C37 showed extremely high antiviral potency in single cycle and replication-competent viral assays against R5-tropic viruses, with IC(50) values as low as 0.004 nm. This inhibition was somewhat strain-dependent and was up to 100-fold better than the RANTES variant alone or in combination with unlinked C37. The chimeric inhibitors also fully retained the antiviral activity of C37 against X4-tropic viruses, and this inhibition can be further enhanced significantly if the target cell co-expresses CCR5 receptor. On human peripheral blood mononuclear cells, the inhibitors showed very strong inhibition against R5-tropic Ba-L strain and X4-tropic IIIB strain, with IC(50) values as low as 0.015 and 0.44 nm, which are 45- and 16-fold better than the parent inhibitors, respectively. A clear delivery mechanism requiring a covalent linkage between the two segments of the chimera was observed and characterized. Furthermore, the two chimeric inhibitors are fully recombinant and are easily produced at low cost. These attributes make them excellent candidates for anti-HIV microbicides. The results of this study also suggest a potent approach for optimizing existing HIV entry inhibitors or designing new inhibitors.

CCR5 Antagonist TD-0680 Uses a Novel Mechanism for Enhanced Potency Against HIV-1 Entry, Cell-mediated Infection, and a Resistant Variant

Advances of CCR5 antagonists: From small molecules to macromolecules

The Research of Anti-HIV Drugs Small Molecular CCR5 Antagonist

Recent Progress in Small Molecule CCR5 Antagonists As Potential HIV-1 Entry Inhibitors

CB‐0821, a novel CC chemokine receptor 5 (CCR5) inhibitor with improved binding efficacy proposed as anti‐HIV candidate: Computational and in vitro approach

Medicinal chemistry of small molecule CCR5 antagonists for blocking HIV-1 entry: a review of structural evolution.

Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives As a Novel Series of CC-Chemokine Receptor 5 Antagonists.

Chemokine Receptor CCR5 Antagonist Maraviroc: Medicinal Chemistry and Clinical Applications.

Molecular binding mode of PF-232798, a clinical anti-HIV candidate, at chemokine receptor CCR5

CCR5 Editing by Staphylococcus Aureus Cas9 in Human Primary CD4+ T Cells and Hematopoietic Stem/progenitor Cells Promotes HIV-1 Resistance and CD4+ T Cell Enrichment in Humanized Mice

Small Molecular CCR5 Antagonists As HIV Inhibitors:A Review of Recent Research

Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy

Highly Potent Chimeric Inhibitors Targeting Two Steps of HIV Cell Entry

Targeted Immuno-Antiretroviral to Promote Dual Protection against HIV: A Proof-of-Concept Study

Targeting CCR5 for anti-HIV research

Progress in the Research of Small Molecule CCR5 Antagonists

The Membrane-Proximal Region of C–C Chemokine Receptor Type 5 Participates in the Infection of HIV-1

Recent advances in the development of small-molecule CCR5 inhibitors for HIV.

Research and Development of CCR5-targeted Small Molecule Anti-AIDS Drugs

Identification of Potential CCR5 Inhibitors Through Pharmacophore-Based Virtual Screening, Molecular Dynamics Simulation and Binding Free Energy Analysis

Discovery of 3-{5-[(6-amino-1h-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a Potent, Orally Bioavailable HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor with Improved Potency Against Key Mutant Viruses.